Company Overview

Kodiak Sciences Inc. is a U.S.-based biopharmaceutical company focused on developing therapeutics for retinal diseases and chronic eye disorders. The company operates within the biotechnology and ophthalmology industries, with a primary emphasis on therapies designed to improve durability, efficacy, and patient outcomes in diseases such as wet age-related macular degeneration (wet AMD), diabetic retinopathy, diabetic macular edema (DME), and retinal vein occlusion. Kodiak’s core business model centers on research, clinical development, and commercialization of proprietary ophthalmic biologics and drug delivery technologies.

The company’s principal strategic asset has been its antibody biopolymer conjugate (ABC) platform, which was designed to extend durability and improve retinal drug delivery. Kodiak became publicly traded after completing its initial public offering in 2018 and has focused heavily on advancing late-stage retinal disease programs. Historically, the company’s lead product candidate was tarcocimab tedromer, although development priorities have evolved following clinical trial outcomes and portfolio reassessments disclosed in public filings and investor communications. Kodiak’s positioning has been tied to its attempt to reduce treatment burden in retinal disease management through longer-lasting therapies.

Business Operations

Kodiak Sciences generates value primarily through the development of proprietary ophthalmology therapeutics and intellectual property associated with retinal disease treatment technologies. The company’s operations are largely concentrated in clinical research, regulatory development, and manufacturing preparation activities rather than commercial product sales, as it has not historically maintained a broad commercialized product portfolio. Its principal operating activities include advancing retinal biologic candidates through clinical trials, managing regulatory submissions, and supporting platform technology development.

The company’s operations are primarily based in the United States, with clinical trial activity extending internationally through research sites and development partnerships. Kodiak has controlled proprietary technology assets associated with its ABC Platform and related ophthalmic biologic engineering capabilities. Revenue historically has been limited and primarily associated with collaboration arrangements, financing activities, or investment income rather than recurring product sales. Public disclosures identify collaborations with contract research organizations, manufacturing partners, and clinical development vendors that support global trial execution and biologics production.

Strategic Position & Investments

Kodiak Sciences has pursued a strategy centered on developing longer-acting retinal therapeutics intended to reduce injection frequency for patients with chronic ophthalmic diseases. The company has invested substantially in clinical-stage biologics development, manufacturing infrastructure preparation, and platform technologies intended to improve drug stability and retinal durability. Strategic efforts have focused on addressing large ophthalmology markets where treatment adherence and injection burden remain significant challenges.

The company’s investment priorities have included advancing retinal pipeline candidates and evaluating additional ophthalmic applications for its platform technologies. Kodiak has also directed resources toward intellectual property development and biologics manufacturing capabilities. Following mixed or unfavorable outcomes in certain late-stage clinical programs, the company publicly indicated strategic reassessments regarding pipeline prioritization and capital allocation. Data regarding future commercial partnerships or major acquisition activity remains limited based on available public sources.

Geographic Footprint

Kodiak Sciences is headquartered in Palo Alto, California, and its operational footprint is primarily concentrated in the United States. The company conducts clinical development activities across multiple geographic regions through international trial sites and outsourced research partnerships. Its regulatory and commercialization ambitions have historically targeted major ophthalmology markets including North America, Europe, and selected Asia-Pacific regions.

Although Kodiak does not maintain the same global commercial infrastructure as large multinational pharmaceutical companies, its clinical development programs have involved multinational patient enrollment and internationally coordinated regulatory activities. The company’s influence outside the United States has primarily been associated with clinical research participation and potential future market opportunities in retinal therapeutics rather than broad operational ownership abroad.

Leadership & Governance

Kodiak Sciences was founded by researchers and biotechnology entrepreneurs focused on retinal disease innovation. The company’s leadership strategy has emphasized long-term ophthalmology platform development, scientific differentiation, and the advancement of durable retinal therapeutics through proprietary biologic engineering technologies. Governance and strategic oversight are provided through executive management and the company’s board of directors, with leadership frequently emphasizing clinical execution, capital discipline, and scientific innovation in public filings and investor materials.

Key executives have included:

• Victor Perlroth, MD – Chief Executive Officer
• Thomas M. Aaberg Jr., MD – Chief Medical Officer
• Jason Ehrlich, MD, PhD – Former Chief Medical and Development Officer
• Robert Bhisitkul, MD, PhD – Senior Medical Advisor and ophthalmology leader
• Stephen Brunner – Chief Financial Officer

Leadership information and executive roles have changed periodically based on company filings and public disclosures. Investors should consult the most recent SEC filings and company governance materials for current executive appointments and board composition.